Clinical Trials Browser

Not yet recruiting × OTHER × dalpiciclib × Clear all

NCT07307287 2025-12-29

SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07179939 2025-09-18

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

Phase 2 Not yet recruiting

HER2-positive Breast Cancer

NCT06556862 2025-08-13

Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor

Phase 2 Not yet recruiting

HR+/HER2- Advanced Breast Cancer

NCT06810492 2025-03-17

The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment

Phase NA Not yet recruiting

Breast Neoplasms

NCT06711094 2024-12-02

Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABC

Phase NA Not yet recruiting

HR+/HER2- Advanced Breast Cancer

NCT06605690 2024-09-20

An Exploratory Clinical Study of Dalpiciclib an&Amp;#39;d Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast Cancer

Phase NA Not yet recruiting

Breast Neoplasms

NCT06552858 2024-08-14

Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer

Phase 2 Not yet recruiting

Ovarian Neoplasms

NCT06199271 2024-01-22

Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05431504 2022-06-24

The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis

Phase 2 Not yet recruiting

Advanced Breast Cancer